Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma

Summary

The goal of this clinical research study is to learn if ibrutinib can help to control lymphoma in patients who have had an autologous stem cell transplant (a transplant using your own stem cells). The safety of this drug will also be studied.

Timeline

Start

2016-06-03

Primary completion

2017-12-22

Completion

2017-12-22

Outcome

Outcome not reported

Stopped (Enrollment): “Slow Accrual”

Drugs

Indications